Clinical trials: Cerebral Glioblastoma
Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme
In the current proposed trial the role of the low-dose WBRT (0.15 Gy) would be to safely treat the microscopic distant GBM cells outside of the high dose RT region and sensitize the gross tumor, while the focal radiation dose…
- Trial name
- GCC 1224 (NCT01822275)
- Testing
- Chemotherapy with Temodar., Radiation therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Maryland, Baltimore
Glioma of Brain
A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.
- Trial name
- NCT03650257
- Testing
- gp96, Temozolomide, radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Cure&Sure Biotech Co., LTD
Brain and Central Nervous System Tumors
Suramin in Treating Patients With Recurrent Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary…
- Trial name
- NCT00002639
- Testing
- chemotherapy, suramin
- Where
- United States
- Sponsor
- Emory University
Glioblastoma Multiforme, Glioma of Brain
V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer
The Phase II study to determine the safety and efficacy of V-Boost in treating a type of brain cancer called Glioblastoma Multiforme (GBM).
- Trial name
- GBM (NCT03916757)
- Testing
- V-Boost
- Where
- Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
Brain and Central Nervous System Tumors
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
Phase I/II trial to estimate the maximum tolerated dose of imatinib mesylate in newly diagnosed brain stem gliomas and recurrent high grade gliomas and to assess the effectiveness of imatinib mesylate in treating young patients…
- Trial name
- NCT00021229
- Testing
- imatinib mesylate, local irradiation therapy
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Gliosarcoma
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Background: Growth of new blood vessels (angiogenesis) provides many tumors, including brain tumors, with needed nutrients and oxygen for cancer cells to survive.
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00995007
- Testing
- ZD6474 (Vandetanib), Carboplatin
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma
FMISO-PET in Brain Tumors and SCS Effect
The aim of this study is to assess, with 18F-FMISO PET, hypoxia in high grade gliomas and changes by spinal cord stimulation in a subset of patients.
- Trial name
- FMISOPETSCS (NCT01868906)
- Testing
- 18F-FMISO, PET without SCS, SCS
- Where
- 2 sites in Spain
- Volunteers
- 6 people
- Sponsor
- Bernardino Clavo, MD, PhD
Glioblastoma, Cerebral Edema
Antisecretory Factor in Primary Glioblastoma 1
This is a non-randomised, open-label, single center-centre, Phase I-II study in patients with newly diagnosed glioblastoma. 5 patients with newly diagnosed glioblastoma are enrolled in the study and will receive an egg powder…
- Conditions
- Glioblastoma, Cerebral Edema, Chemotherapy Effect
- Trial name
- AFGBM1 (NCT04116138)
- Testing
- Salovum
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Peter Siesjö
Glioblastoma
Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens
Eligible adult patients with new diagnosis of gliobastoma are enrolled to receive 3 weekly vaccinations of the study drug PEP-CMV 1-3 days following standard of care chemoradiation.
- Trial name
- PERFORMANCE (NCT01854099)
- Testing
- PEP-CMV
- Sponsor
- University of Florida
Glioblastoma
Proteome-based Personalized Immunotherapy of Glioblastoma
Trial Hypothesis: Acute, progressing lethal neurooncological process can be transferred into chronic and non-lethal, the survival rates and life quality can be improved by of control of tumor cells (TCs) quantity and targeted…
- Trial name
- NCT01759810
- Testing
- Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- NeuroVita Clinic
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT00303940
- Testing
- carboplatin, talabostat mesylate, temozolomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Glioblastoma Multiforme of Brain
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients
In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC)…
- Trial name
- ADDIT-GLIO (NCT02649582)
- Testing
- Dendritic cell vaccine plus temozolomide chemotherapy
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Antwerp
Malignant Tumors, Brain Lymphoma
Usefulness of Gadovist-enhanced FLAIR Imaging
Polyplastic glioblastoma and metastatic brain cancer are the most common malignant brain tumors in adults. The primary diagnostic test for tumors in the brain shows magnetic resonance imaging or similar imaging findings…
- Conditions
- Malignant Tumors, Brain Lymphoma, CNS Lymphoma
- Trial name
- NCT05293990
- Testing
- Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Ryoo, In Seon
Glioblastoma, Anaplastic Astrocytoma
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade…
- Trial name
- NCT00431561
- Testing
- AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV
- Where
- 36 sites in Austria, Georgia and 4 more
- Volunteers
- 141 people
- Sponsor
- Isarna Therapeutics GmbH
Primary Brain Tumor, Glioblastoma
Temozolomide in Elderly Patients With KPS < 70
The management of glioblastoma in elderly patients with poor performance status (KPS<70) is unsettled. This single arm phase 2 trial trial was designed to evaluate the efficacy and safety of temozolomide alone in this population
- Trial name
- TAG (NCT01242566)
- Testing
- Temozolomide
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain and Central Nervous System Tumors
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor.
- Trial name
- NCT00027625
- Testing
- gefitinib, temozolomide
- Where
- 11 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma, Glioblastoma
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
- Trial name
- NCT03551249
- Testing
- Focused ultrasound (FUS)
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
Leukoencephalopathy
Study of Neurological Complication After Radiotherapy for High Grade Glioblastoma
The survival time and the number of long time survivors after radiotherapy in brain cancer patients have increased for the last decades.
- Trial name
- EPIBRAINRAD (NCT02544178)
- Testing
- brain radiotherapy
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Sophie JACOB
Glioblastoma
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months
- Trial name
- NCT00171938
- Testing
- imatinib mesylate
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Novartis
Brain and Central Nervous System Tumors
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00516282
- Testing
- CLORETAZINE, temozolomide
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University